logo
Windsor's key strategy to reduce emissions 'too costly' without financial help

Windsor's key strategy to reduce emissions 'too costly' without financial help

CBC27-03-2025
City staff in Windsor, Ont., say a low interest loan program homeowners could use to make their house more energy efficient is too expensive for the city to implement.
Council told staff in 2018 to create a program that would help 80 per cent of the city's homes become up to 50 per cent more energy efficient by 2041.
But a report to council now finds completing the goal of retrofitting 57,200 homes would take 100 years based on uptake in other retrofit programs.
The program is pitched in Windsor's Community Energy Plan as the most effective way to cut energy consumption and community-wide greenhouse gas emissions.
That's because 21 percent of community-wide emissions are from heating, cooling and powering houses that are on average 20 years older than Ontario's average.
But after years of study and design work, senior administration say the Windsor Residential Deep Energy Efficiency Retrofit (R-DEER) program is too expensive to implement and unlikely to achieve the initial target.
Windsor's Citizens Environment Alliance says not moving forward with the program would leave the city's climate-action efforts "in shambles."
How the program would work
The R-DEER plan staff developed would let homeowners borrow between $10,000 and $40,000, depending on the value of their home, to cover energy efficient upgrades with a low interest rate.
Some examples of projects the money could be spent on include energy efficient windows and doors, better insulation, and electric vehicle charging stations.
Homes would need to be at least 20 years old with a creditworthy homeowner.
City staff previously said the average home in Windsor was built in the 1960s and uses 20 per cent more energy than the average home in Ontario.
The proposed program would offer energy coaches that would guide people through financing and program options.
The city could also offer a grant to pay for energy audits to help owners understand the potential benefits of upgrades while reducing upfront costs.
People could use a Local Improvement Charge to pay for the retrofits, which is a loan tied to the property and repaid through property taxes.
How much it would cost
In the report to council, administration lays out a 10-year funding model aimed at making 80 per cent of Windsor homes 50 per cent more energy efficient.
The total cost would be $200-million, with $154-million over those 10 years being loans for work that the city is expected to recover.
However, Windsor's city treasurer Janice Guthrie warns the loans would require a partnership with a financial institution and would then be considered debt.
"That would really put a stranglehold on anything else we would be wanting to do in terms of capital projects for the city," said Guthrie.
"Some of those could be at jeopardy of not being able to move forward."
Administrating the plan would require 10 full-time equivalent jobs a few years after launching the program, according to the report to council.
Meeting initial goal would take 100 years
Staff also write that getting the uptake required to meet the emission and energy consumption targets set by council "will be extremely challenging."
"Our findings suggest that accelerating the rate of deep retrofits in Windsor (and Canada) will require substantial investments from federal and provincial governments," wrote a consultant in a market validation study.
"Windsor is currently on track to miss the climate targets set out in its Community Energy Plan and will struggle to meet them without further investment in residential deep retrofit incentive programs like Canada Greener Homes."
Meeting Windsor's 2041 climate targets would require 80 per cent of homes in the city become more energy efficient, but the market validation study found it's likely it would only see 10 per cent of homes retrofitted using the program in that timeline.
The study found there are enough contractors to complete the work in the launch of the program, however, also found the proposed uptake was "overly aggressive, as they overestimated participation when compared with utility and government retrofit programs."
"Even if we were to execute the program in its entirety," said commissioner of economic development Jelena Payne.
"We would still not be able to meet the targets that have been identified by upper levels of government and city council."
Citizens group, councillor want the program implemented
Derek Coronado, the executive director of Citizens Environment Alliance Southwestern Ontario, said the program should be supported by council to help people take action in a climate crisis.
He said the city has great plans but they need to be acted on to see results
"The city has not followed through on the important things of taking climate action seriously and that means implementing the stages of your plan that you need to implement," said Coronado.
He said the program, if implemented, would create work for contractors and should be looked at as an economic development tool as well as a way to slow climate change.
"Time and time again administration reports have said the most costly aspect of climate change is deferring, delaying or not dealing with climate change up front," said Coronado.
"That's exactly what the city has been doing. It's actually kicking the cost down the road."
Staff are asking council to receive the report and not implement the program but instead ask the federal government for more money to help cover costs.
Coun. Kieran McKenzie chaired the council committee that discussed the report on Wednesday and opposed that motion.
He highlighted how the program has been identified by staff as "fundamental to the success" of the city's climate action plans.
"We don't have other plans to get closer that I see to achieving our climate change goals," he said.
"We often don't make the hard decisions, and this is a hard one."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

British Open joins US Open in leaving prize fund at same level
British Open joins US Open in leaving prize fund at same level

Winnipeg Free Press

timea day ago

  • Winnipeg Free Press

British Open joins US Open in leaving prize fund at same level

PORTRUSH, Northern Ireland (AP) — The British Open is leaving the total prize money at $17 million, the first time since 2012 the R&A has chosen not to increase the purse. The U.S. Open also did not boost its purse this year at Oakmont. The winner this week at Royal Portrush will receive $3.1 million, the same amount Xander Schauffele earned last year at Royal Troon. The four majors had been gradually increasing their prize money in recent years. The Masters increased its prize fund by $1 million to $21 million. The PGA Championship went up $500,000 to $19 million. The U.S. Open left its purse at $21.5 million, still the highest of the four majors. It's an example that the biggest championships are not about prize money, but green jackets and claret jugs. The Players Championship on the PGA Tour has a $25 million purse. PGA Tour signature events and Saudi-funded LIV Golf events have $20 million prize funds. ___ AP golf: Thursdays Keep up to date on sports with Mike McIntyre's weekly newsletter. The U.S. Open also chose not to increase the purse this year, leaving it at $21.5 million. The Masters was at $20 million this year.

Can Intel Be Leaner & More Agile by Laying Off 529 Employees?
Can Intel Be Leaner & More Agile by Laying Off 529 Employees?

Globe and Mail

time5 days ago

  • Globe and Mail

Can Intel Be Leaner & More Agile by Laying Off 529 Employees?

Intel Corporation INTC is reportedly laying off 529 employees across four locations in Oregon to minimize operating costs and reduce organizational complexity to better serve customers. These include software and hardware engineers, developers, managers, scientists and other domain specialists with backgrounds in artificial intelligence (AI) and cloud computing. A lion's share of the job cuts is taking place at Intel's Jones Farm Campus, which focuses on chip design work as well as research and development (R&D). The other facilities that are witnessing job cuts include the Aloha, Hawthorne Farm and Ronler Acres campuses, which support semiconductor research and manufacturing. Oregon boasts the largest number of Intel's facilities and workforce, with about 22,000 employees. By trimming its huge employee base, the company aims to eliminate unnecessary bureaucracy levels and become leaner and more agile, regaining its competitive edge. This follows a similar exercise a few days back, when the company decided to wind up its automotive architecture business as part of a broader restructuring process to trim operating costs and boost liquidity. Intel expects to free up significant resources by winding down this peripheral unit, thereby making more money available for R&D funding in the core PC and data center segments. Intel has been investing in expanding its manufacturing capacity to accelerate its IDM 2.0 (Integrated Device Manufacturing) strategy. Interim management is committed to keeping the core strategy unchanged despite efforts to drive operational efficiency and agility. The company is emphasizing the diligent execution of operational goals to establish itself as a leading foundry. It is focusing on simplifying parts of its portfolio to unlock efficiencies and create value. Other Tech Firms Laying Off Employees Microsoft Corporation MSFT has laid off 6,000-7,000 employees as part of a broader restructuring strategy focused on boosting AI innovation and reducing organizational layers. The job cuts are purportedly aimed at reducing redundancy, particularly in middle management and support functions. Microsoft is reallocating the freed-up resources toward high-growth AI areas like Azure AI, Copilot and custom silicon. In addition to some non-core roles within the Azure cloud, Microsoft laid off employees from its legacy hardware operations and gaming divisions. Meta Platforms, Inc. META has conducted multiple smaller rounds of layoffs this year, affecting around 3,600 employees across departments. A majority of the job cuts occurred in Meta's metaverse division, Reality Labs, as the company trimmed roles in hardware, AR/VR and software development that were deemed non-core. In addition, Meta eliminated various non-essential jobs while prioritizing AI-powered discovery businesses. INTC's Price Performance, Valuation and Estimates Intel shares have declined 30% over the past year against the industry 's growth of 23.5%. Going by the price/sales ratio, the company's shares currently trade at 1.97 forward sales, lower than 14.95 for the industry. Earnings estimates for 2025 have decreased 6.7% to 28 cents per share over the past 60 days, while the same for 2026 have declined 6.3% to 74 cents. Intel stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Higher. Faster. Sooner. Buy These Stocks Now A small number of stocks are primed for a breakout, and you have a chance to get in before they take off. At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We've combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month. You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days. Download the report free now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report

JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?

Globe and Mail

time6 days ago

  • Globe and Mail

JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?

Johnson & Johnson JNJ and Pfizer PFE rank among the world's largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals and medical devices segments. Its pharmaceutical division boasts one of the industry's most varied revenue streams, spanning areas like neuroscience, cardiovascular and metabolic diseases, immunology, oncology, pulmonary hypertension, and infectious diseases. Pfizer, meanwhile, holds a strong leadership position in oncology and also maintains a solid presence in inflammation and immunology, rare diseases and vaccines. Both companies have promising R&D pipelines capable of delivering innovative treatments and supporting future growth. But which stock presents a better investment opportunity right now? Let's dive into their fundamentals, growth outlook and potential challenges to make a well-informed comparison. The Case for J&J J&J's biggest strength is its diversified business model, which helps it to withstand economic cycles more effectively. It operates through more than 275 subsidiaries. J&J's Innovative Medicine unit is showing a growth trend. The segment's sales rose 4.4% in the first quarter of 2025 on an organic basis despite the loss of exclusivity (LOE) for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign. In 2025, J&J expects growth in the Innovative Medicine segment in the face of Stelara biosimilar entrants to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey, and new indications for Tremfya and Rybrevant. J&J expects its Innovative Medicine business to grow 5-7% from 2025 to 2030. J&J is also making rapid progress with its pipeline and has been on an acquisition spree lately, which has strengthened its pipeline. On the flip side, sales in J&J's MedTech business are facing continued headwinds in the Asia Pacific, specifically in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anti-corruption campaign. J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses. The company lost U.S. patent exclusivity of its blockbuster drug, Stelara, in 2025. The launch of generics is expected to significantly erode the drug's sales, hurting J&J's sales and profits in 2025. J&J faces more than 62,000 lawsuits for its talc-based products, primarily baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. J&J insists that its talc-based products are safe and do not cause cancer. The company permanently discontinued the sales of its talc-based Johnson's Baby Powder. In April, a bankruptcy court in Texas rejected J&J's proposed bankruptcy plan to settle its talc lawsuits after a two-week trial in Houston. J&J will go back to the traditional tort system to fight the lawsuits individually with its bankruptcy strategy to settle the lawsuits failing for the third time. The Case for PFE Pfizer is one of the largest and most successful drugmakers in oncology. The 2023 acquisition of Seagen strengthened its position in oncology further. After witnessing possibly its worst slowdown in 2023/early 2024, the company seems to be gradually making a comeback and entering a transition phase. With its COVID-related uncertainties diminishing, its revenue volatility is declining. Though COVID revenues are declining, Pfizer's non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Pfizer's significant cost reduction and efforts to improve R&D productivity measures should drive profit growth. However, Pfizer faces its share of challenges, the key being declining sales of its COVID-19 products. Pfizer also expects a significant impact from the loss of patent exclusivity in the 2026-2030 period, as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, will face patent expirations. The Medicare Part D redesign is also expected to hurt sales of Pfizer's higher-priced drugs like Vyndaqel, Ibrance and Xeljanz in 2025. Though Pfizer does not expect strong top-line growth over the next three years due to the LOEs, it expects EPS growth. How Do Estimates Compare for JNJ & PFE? The Zacks Consensus Estimate for J&J's 2025 sales and EPS implies a year-over-year increase of 2.8% and 6.4%, respectively. The Zacks Consensus Estimate for 2025 earnings has risen from $10.60 per share to $10.62 per share for 2025 and from $10.98 per share to $11.00 per share over the past 30 days. JNJ Estimate Movement The Zacks Consensus Estimate for Pfizer's 2025 sales and EPS implies a year-over-year decline of 0.6% and 1.6%, respectively. The Zacks Consensus Estimate for earnings has remained unchanged at $3.06 per share for 2025 and at $3.09 per share for 2026 over the past 30 days. PFE Estimate Movement Price Performance and Valuation of J&J & PFE Year to date, J&J's stock has risen 9.5%, while Pfizer's stock has failed to deliver any returns compared with the industry 's increase of 0.2% Pfizer looks more attractive than J&J from a valuation standpoint. Going by the price/earnings ratio, J&J's shares currently trade at 14.41 forward earnings, slightly lower than 14.93 for the industry. Pfizer's shares currently trade at 8.33 forward earnings, significantly lower than the industry and the stock's 5-year mean of 10.87. Johnson & Johnson's dividend yield is 3.3%, while Pfizer's is 6.7%. Johnson & Johnson's return on equity of 33.5% is higher than Pfizer's 20.3%. PFE or JNJ: Which is a Better Pick? Though Pfizer is on a recovery path, the upcoming patent cliff raises uncertainty. We would like to wait and see how the company navigates through the challenge. Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Meanwhile, J&J, with its Zacks Rank #2 (Buy), improving growth prospects, rising estimates, and recent price appreciation, may prove to be a better pick than Pfizer. J&J has shown steady revenue and EPS growth for years. Though the softness in the MedTech unit and the legal battle surrounding its talc lawsuits are a concern, its Innovative Medicines unit is showing a growing trend. J&J considers 2025 to be a 'catalyst year,' positioning the company for growth in the second half of the decade. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. While newly launched products should drive growth in the Innovative Medicines segment in the second half, the MedTech segment may benefit from new products and easier comps. J&J expects growth to accelerate from 2026 onward. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store